Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 20/20 | 0.82 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.55 |
| ▸ | CALCA | P06881 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4560453 | 0.90 | CALCRL (1.00) | CALCRLCYP3A4 | |
| SCHEMBL442897 | 0.90 | CALCRL (1.00) | CALCRLCYP3A4 | |
| SCHEMBL4054553 | 0.88 | CALCRL (0.79) | CALCRLCYP3A4 | |
| SCHEMBL4223837 | 0.88 | CALCRL (0.79) | CALCRLCYP3A4 | |
| SCHEMBL16817037 | 0.84 | CALCRL (0.71) | CALCRLRAMP1CALCACYP3A4 | |
| SCHEMBL16817034 | 0.84 | CALCRL (0.71) | CALCRLRAMP1CALCACYP3A4 | |
| SCHEMBL3780298 | 0.83 | CALCRL (0.59) | CALCRL | |
| SCHEMBL13747500 | 0.81 | CALCRL (0.56) | CALCRL | |
| SCHEMBL5108092 | 0.80 | CALCRL (1.00) | CALCRLCYP3A4 | |
| SCHEMBL4051284 | 0.80 | CALCRL (1.00) | CALCRLCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140128375-A1 | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2014-05-08 | — | — | US | disclosed |
| US-20140128375-A1 | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2014-05-08 | — | — | US | disclosed |
| US-20120065190-A1 | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
| US-20120065190-A1 | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
| WO-2008085317-A1 | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128375-A1 | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CALCRL | CALCRL 3/4885RAMP1 9/4885CALCA 14/4885 |
| US-20120065190-A1 | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CALCRL | CALCRL 3/4885RAMP1 9/4885CALCA 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.